Duration of Postoperative Analgesia with Intravenous Nalbuphine versus Intravenous Butorphanol in Patients Undergoing Short Surgical Procedures under TIVA

Sanjot Ninave a†, Sudhir Ninave b¥, P. Shiras a‡, Neeta Chaudhari a#
Aruna Chandak a† and Vijay Chandak a#

a Department of Anaesthesiology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science, India.
b Department of Forensic Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science, India.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2022/v34i5B34677

ABSTRACT

Aims and Objectives: To compare the duration of post operative analgesia of nalbuphine 0.3 mg/kg IV and butorphanol 0.04 mg/kg IV in patients posted for short surgical procedures under TIVA. Also to observe the sedation score as well as the side effects like nausea, emesis, pruritis, hypotension, respiratory depression.

Materials and Methods: By closed envelope technique, sixty female patients of ASA Class I and II aged 20-60 years, who were posted for short gynaecological surgeries under TIVA were randomly allocated into two groups: Group N (nalbuphine) and Group B (butorphanol). Just prior to surgery, Group N patients got IV Nalbuphine 0.3 mg/kg, while Group B patients received IV Butorphanol 0.04 mg/kg. Patients were asked to rate their pain intensity on a VAS scale in the course of the
postoperative period, and the duration of postoperative analgesia was compared between the two
groups. The Modified Ramsay sedation scale was exercised to assess sedation at the time of pain
complaint, and patients were additionally monitored for 24 hours post the surgery for any adverse
or side effects.

Results: In group N, 63.33% of patients had duration of pain relief ranging 31-50 minutes, with
mean duration of analgesia being 46.33 ± 2.06 minutes. In group B, 60% of patients had duration of pain
relief ranging from 11-30 minutes, with mean duration being 19.167 ± 1.68 minutes. In group N,
63.33% of patients had score for sedation as 3 and rest (36.67%) had a
score for sedation as 2. In group B, 80% of patients had a score for sedation as 2 and rest (20%) had a score for sedation
as 1.

Conclusion: When compared to IV Butorphanol, intravenous Nalbuphine delivers a more effective
post-operative analgesia with better sedation. IV Nalbuphine is recommended for post operative
analgesia in patients undergoing short surgical procedures. Both the drugs did not cause any side
effects.

Keywords: Postoperative analgesia; intravenous; nalbuphine; butorphanol.

1. INTRODUCTION

TIVA (Total intravenous anaesthesia) is a type of
general anaesthetic used for short surgical
procedures that involves a mix of drugs administered solely through the intravenous
route, in the absence of inhalational anaesthetics
(gas anaesthesia) [1].

Some of the potential benefits of total intravenous anaesthesia (TIVA) include reduced
nausea and vomiting post operatively, more anticipated and prompt recovery, significant
hemodynamic stability, hypoxic pulmonary vasoconstriction is preserved, lowering in intra
cerebral pressure (ICP) as well as a lower risk of organ toxicity. When utilised in circumstances
where post-operative pain control is essential, TIVA (total intravenous anaesthesia) is merely an
anaesthetic method [2].

TIVA can be carried out using a single medication or in combination with other IV drugs.
Hypnotics and short-acting opioids are two of the
most regularly used medication classes [3].

Propofol is the sole active intravenous drug
(hypnotic) currently appropriate for anaesthesia induction as well as its maintenance. Many advantages of propofol-based TIVA include quick recovery of psychomotor function and consciousness, antiemetic action, and a reduced incidence of postoperative nausea and emesis
[4].

For the majority of surgery patients, pain perception is a serious concern. Postoperative
pain is a type of acute pain that triggers a systemic stress response [5], which
includes neuroendocrine, immunological, and
haematological reactions. Catabolism of stored
body fuels is the overall metabolic effect [6].

Despite advances in pain relief management, most of the patients carry on to suffer from
excruciating pain following surgery [7]. The noval
anaesthetic aims not just in pain reduction but it
also aims at the betterment of the quality of life of
the sufferer and his/her speed recovery with
lowering medical costs.

For a long time, opioids have been the go-to
treatment for immediate postoperative pain,
especially moderate to severe pain. Though, mu
agonists such as morphine can cause major
adverse effects such as delayed respiratory
depression pruritus, increased frequency of
micturition, poor bladder control (retention),
nausea, vomiting, etc. These side effects could
make patients uncomfortable and lengthen their
stay in the hospital, limiting their effectiveness as
a post-operative pain reliever.

Both Butorphanol and Nalbuphine are partial
agonist–antagonists, acting as agonists on the
kappa receptor while acting as antagonists or
partial agonists on the mu receptor. Analgesia
with less undesired side effects, such as
respiratory depression, are among the
advantages of partial agonists. They can be
administered intramuscularly, intravenously,
epidurally, or transnasally. When compared to
powerful opioids like morphine or fentanyl, they
are commonly available and unrestricted.

1.1 Aims and Objectives

Aim: To assess the efficacy of inj. Nalbuphine
given intra venously with Intra venous inj.
butorphanol in patients posted for short surgical procedures under Total Intravenous anaesthesia (TIVA).

**Objectives:**

**Primary objective:** To compare the duration of post operative analgesia of intravenous nalbuphine 0.3 mg/kg and intravenous butorphanol 0.04 mg/kg in patients posted for short surgical procedures under Total Intravenous anaesthesia (TIVA).

**Secondary objectives:** To observe:

1) The sedation score
2) Side effects like nausea, emesis, sedation, shivering, pruritis, depressed respiration.

**1.2 Sample Size Calculation**

Sample size calculation was done using OpenEpi, version 3. Assuming duration of analgesia of 9.07 hours and standard deviation of 4.71 hours, keeping the power at 80% and confidence interval at 95% (alpha error at 0.05) a sample of 28 patients would be required to detect the minimum of 50% difference in the duration of analgesia between the two groups. We include 30 patients in each group to compensate for the possible dropouts.

**2. MATERIALS AND METHODS**

Sixty female patients undergoing short gynecological procedures under Total Intravenous anaesthesia (TIVA) were allocated randomly into two equal groups of 30 each by closed envelope technique. Group N who were given intravenous Inj. Nalbuphine 0.3mg/kg and Group B, who were given intravenous Inj. Butorphanol 0.04 mg/kg.

After preoperative / pre anaesthetic check up, patients were enrolled in the study as per following criteria.

**2.1 Criteria for Inclusion**

1. Patients classified as ASA grade I and II
2. Female patients in age group of 20-60 years
3. Posted for surgeries short gynaecological procedures like dilatation & curettage and suction evacuation under Total Intravenous anaesthesia (TIVA)
4. Patients who gave consent to participate in study.

**2.2 Criteria for Exclusion**

1. Patients who are allergic to the drugs.
2. Patients who are on
   - Oral anticoagulant therapy.
   - Neuroleptic agent.
   - Mono amino oxidase inhibitor.
3. Patients with
   - History of epilepsy/ seizure.
   - Increased intracranial tension.
   - History of motion sickness.
   - History of opioid use over the last 1 month.
4. Patients not willing to participate in study.
5. Intraoperative sedation or analgesic given Intravenously or intra muscularly.

On the day of operation, an informed written consent was obtained. The Visual analogue pain scale was taught to all of the patients (VAS) and pain descriptor terms in a language they understood.

The visual analogue scale, which is described below, was used to assess pain.

The Visual Analogue Scale (VAS) is a 10-centimeter line with two end points: "no pain" and "pain as bad as it gets." On this line, the patient is requested to make a mark reflecting the severity of the pain. The VAS score is calculated by measuring the distance in centimeters between the end of the scale that indicates "no pain" and the point indicated by the patient [8].

On the operating room table, baseline heart rate (HR), blood pressure (BP), respiration rate (RR), SPO2 and temperature (in degree celcius) were noted.

Patients in both the groups were given intravenous Inj. Glyco 0.2mg, intravenous Inj. Midaz 1mg and study drug intravenously (nalbuphine or butorphanol) and intravenous Inj. Propofol 2 mg/kg for induction and supplementation as required (0.25 mg/kg) through out the procedure.

No other analgesics or sedatives drug were given intraperoperatively. No inhalation agents were used intraoperatively.

Intraoperative haemodynamic monitoring was done as per conventional method.

Patients were sent to a post-operative recovery room after the surgery, where vital signs such as
baseline heart rate (HR), blood pressure (BP), respiration rate (RR), SPO2 and temperature (in degree celcius) were checked every 30 minutes.

When the patient complains of pain, VAS>4, the duration of postoperative analgesia was documented. (In the recovery room, the time interval between the onset of analgesia and the patient complaining of pain (i.e. VAS score >4) is regarded as the duration of analgesia).

Any adverse effects like nausea, emesis, pruritis, hypotension, respiratory depression and others were recorded.

3. RESULTS

3.1 Duration of Analgesia

When the patient complains of pain, VAS>4, the duration of postoperative analgesia was documented.

63.33% of patients in group N were having a range of 31-50 minutes of analgesic duration, with a mean analgesic duration being 46.333 ± 2.061 minutes with minimum of 21-30 minutes analgesic duration was seen in 10% of group N participants and a maximum analgesic duration of 61-70 minutes was seen in 6.67% of group N participants.

60% of patients in group B were having a range of 11-30 minutes of analgesic duration, with a mean analgesic duration being 19.167± 1.68 minutes with minimu analgesic duration of 5-10 minutes was seen in 30% of group B participants and a maximu analgesic duration of 31-40 minutes was seen in 10% of group N participants.

When comparing groups N and B, a statistical analysis using a student unpaired t-test revealed that group N had a statistically significant increase in analgesia duration. (t=55.9594 with df-31, p<0.0000001).

3.2 Assessment of Sedation

It was done using Modified Ramsay sedation

In group N, 63.33% of patients were having a sedation score of 3 and rest (36.67%) were having a sedation score of 2.

In group B, 80% of patients were having had a sedation score of 2 and rest (20%) had a sedation score of 1.

3.3 Side Effects

Patients were also observed for 24 hours post operatively for any side effects. None of the patients participated in the study showed any of the side effects like nausea, vomiting, pruritis, respiratory depressions, hypotension or others.

| No pain | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Pain as bad as it can be |
|---------|---|---|---|---|---|---|---|---|---|----|-------------------------|

Fig. 1. Visual analogue scale

Chart 1. Sedation assessment was done using the ‘Modified Ramsay’ scale for sedation, which is as follows [9]

| Definition | Score |
|------------|-------|
| Anxiousness, restlessness, agitation | 01 |
| Cooperative, orientate, calm | 02 |
| Responds only to orders | 03 |
| Response on light glabellar tapping being brisk or strident noise | 04 |
| Response on light glabellar tapping being sluggish or strident noise | 05 |
| Un responsiveness | 06 |
| Analgesic duration (minutes) | Group N No of cases (%) | Group B No of cases (%) |
|-----------------------------|-------------------------|-------------------------|
| 5-10                        | 0 (0)                   | 9 (30)                  |
| 11-20                       | 0 (0)                   | 12 (40)                 |
| 21-30                       | 3 (10)                  | 6 (20)                  |
| 31-40                       | 11 (36.67)              | 3 (10)                  |
| 41-50                       | 8 (26.66)               | 0 (0)                   |
| 51-60                       | 6 (20)                  | 0 (0)                   |
| 61-70                       | 2 (6.67)                | 0 (0)                   |

| Sedation score | Group N Number of cases (in %) | Group B Number of cases (in %) |
|----------------|--------------------------------|--------------------------------|
| 1              | 0 (0)                          | 6 (20)                          |
| 2              | 11 (36.67)                     | 24 (80)                         |
| 3              | 19 (63.33)                     | 0 (0)                           |
| 4              | 0 (0)                          | 0 (0)                           |
| 5              | 0 (0)                          | 0 (0)                           |
| 6              | 0 (0)                          | 0 (0)                           |

### Table 1. Analgesic duration

### Table 2. Sedation score

### 4. DISCUSSION

In our study, 63.33% of patients in group N were having a range of 31-50 minutes of analgesic duration, with a mean analgesic duration being 46.333 ± 2.061 minutes with minimum of 21-30 minutes analgesic duration was seen in 10% of group N participants and a maximum analgesic duration of 61-70 minutes was seen in 6.67% of group N participants. 60% of patients in group B were having a range of 11-30 minutes of analgesic duration, with a mean analgesic duration being 19.167 ± 1.68 minutes with minimum analgesic duration of 5-10 minutes was seen in 30% of group B participants and a maximum analgesic duration of 31-40 minutes was seen in 10% of group N participants.

Regarding the sedation, In group N, 63.33% of patients were having a sedation score of 3 and rest (36.67%) were having a sedation score of 2. In group B, 80% of patients were having a sedation score of 2 and rest (20%) had a sedation score of 1.

Both the drugs used in our study did not showed any of the side effects like nausea, vomiting, pruritis, respiratory depressions, hypotension etc.

Vidhya N et al after comparing the efficacy of butorphanol with nalbuphine for balanced anaesthesia and post-operative analgesia in patients posted for laparoscopic surgery concluded that Butorphanol is more efficacious as an analgesic with better hemodynamic stability than Nalbuphine [10].

Swapna Banerjee and Shaswat Kumar Pattnaik compared post operative analgesia with epidural nalbuphine, butorphanol and fentanyl in lower abdominal surgeries concluded that fentanyl produces the faster onset of analgesia and Butorphanol gives longer duration of analgesia [11].

V.V Lokeshwari et al. [12] compared intramuscular nalbuphine with intramuscular butorphanol for postoperative pain relief concluded that intramuscular nalbuphine group patients were haemodynamically stable with better post operative analgesia.

Praveen P.V.V.S.B et al when IM nalbuphine, butorphanol, and pentazocine were tested for post-operative analgesia in participants having abdominal hysterectomy, concluded that nalbuphine and butorphanol offered superior analgesia than pentazocine [13].

JJ Wang et al. [14] compared analgesic efficacy of epidural butorphanol, nalbuphine, Meperidine and morphine concluded that both epidural nalbuphine and butorphanol demonstrated a very similar analgesic profile and when compared to morphine they exhibit faster onset of action with shorter duration.
Viviane et al. after comparing nalbuphine and butorphanol, either alone or in conjunction with acepromazine, it was found that butorphanol provided superior sedation than nalbuphine when used alone or in combination with acepromazine [15].

Zucker et al in 1987 compared nalbuphine with butorphanol to assess the respiratory depression in patients undergoing procedure under general anaesthesia. They concluded that butorphanol caused significantly pronounced respiratory depression compared to that caused by nalbuphine [16].

J Malek et al. [17] in 1988 compared the post-operative analgesic efficacy of injectable Tramadol (100 mg), Butorphanol (2 mg), Nalbuphine (20 mg), and Buprenorphine (0.3 mg) in adult patients who had had cholecystectomy under GA. They came to the conclusion that all of the medicines were effective in the treatment of post-operative pain. Buprenorphine and tramadol had a longer duration of analgesia and fewer side effects than other opioids.

Babu S et al in 2017 did a study for comparing the post operative analgesic quality as well as the side-effect properties of butorphanol and nalbuphine which are epidurally administered as an adjuvant to 0.2 percent ropivacaine, and it was discovered that ropivacaine with nalbuphine administered via thoracic epidural route is more effectual than ropivacaine with butorphanol for instant post operative pain mitigation in patients subjected for exploratory laparotomy under emergency [18].

Kim DH and Park CH in 1998 conducted a study to find out the analgesic efficacy, dose requirement and adverse reactions of butorphanol and nalbuphine when given via patient controlled analgesia (PCA) along with ketorolac after TAH (total abdominal hysterectomy). They determined that butorphanol and nalbuphine were both effective for PCA for post operative pain relief, and that ketorolac 180 mg with butorphanol 9 mg or nalbuphine 70 mg could be effective for 48-hour pain relief [19].

Priti M Chawda et al in 2010 investigated the efficacy of nalbuphine in reducing increases in heart rate (HR) and mean arterial pressure in response to laryngoscopy and oro-tracheal intubation. Patients received a 0.2 mg/kg IV bolus dose of saline or nalbuphine 5 minutes before laryngoscopy. They found that a dose of 0.2 mg/kg of Nalbuphine avoided a significant increase in heart rate (HR) and mean arterial pressure (MAP) during laryngoscopy and oro-tracheal intubation [20].

Ahsan-ul-Haq et al in 2005 did a study to see how effective nalbuphine is at preventing heart rate (HR) and blood pressure (BP) increases while laryngoscopy and oro-tracheal intubation. They came to the conclusion that 0.2 mg/kg of IV Nalbuphine could avoid a significant increase in HR (heart rate) and MAP (mean arterial pressure) during laryngoscopy and oro-tracheal intubation [21].

5. CONCLUSION

Intravenous Nalbuphine provides longer duration of analgesia and better sedation when compared to intravenous Butorphanol. Both intravenous Nalbuphine and intravenous Butorphanol are safe as no side effects were observed. This study recommends intra venous Nalbuphine as an analgesic for short gynecological procedures under Total intravenous anaesthesia (TIVA).

CONSENT

As per international standard or university standard, written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

After Institutional Ethical Committee clearance, the study was done in the Department of Anaesthesiology, Acharya Vinoba Bhave Rural Hospital, JNMC, Sawangi (Meghe), Wardha district, Maharashtra.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Total intravenous anaesthesia using target controlled infusion – A pocket reference, College of Anesthesiologists, Academy of medicine Malaysia (retrieved 07.05.15).

2. Aunac S, Carlier M, Singelyn F, De Kock M. The analgesic efficacy of bilateral combined superficial and deep cervical plexus block administered before thyroid
surgery under general anesthesia. Anesthesia and Analgesia. 2002;95(3): 746-750.

3. Nora, Fernando Squeff. Total intravenous anesthesia as a target-controlled infusion: An evolutive analysis. Revista Brasileira de Anestesiologia. 2008;58(2):179-192. Retrieved 2015. Available: [link]

4. Absalom A, Struys M. An Overview of TCI, TIVA. Second Edition. 2011; Gent: Academia Press.

5. Desborough JP. The stress response to trauma and surgery. British Journal of Anaesthesia, 2000;85(1):109-117.

6. Joshi G, Ogunnaik B. Consequences of inadequate postoperative pain relief and chronic persistent postoperative pain. Anesthesiology Clinics of North America. 2005;23(1):21-36.

7. Apfelbaum J, Chen Mehta S, Gan T. Postoperative Pain Experience: Results from a National Survey Suggest Postoperative Pain Continues to Be Undermanaged. Anesthesia and Analgesia 2003;97(2):534–540.

8. Kumar P. Methods of clinical pain assessment. In: A Text Book of Pain first edition, New Delhi; Modern publishers. 2005:43-48.

9. Sciedirect.com; 2019 Elsevier B.V.

10. Vidhya N, Prakash V, Irshad B, Kumar V S S. Comparative efficacy of butorphanol versus nalbuphine for balanced anaesthesia and post-operative analgesia in patients undergoing laparoscopic surgery. Indian J Clin Anaesth. 2019; 6(1):143-147.

11. Banerjee S, SK Pattnaik. A comparative study between epidural butorphanol, nalbuphine and fentanyl for postoperative analgesia in lower abdominal surgeries. Asian Journal of Pharmaceutical and Clinical Research. 2017;10(5): 383-8. DOI:10.22159/ajpcr.2017.v10i5.16802

12. Dr. V.V Lokeshwari, Dr. B. Annapurna Sarma, Dr. D.B.V. Madhusudhana Rao. A comparative study of intramuscular nalbuphine with intramuscular butorphanol for the relief of postoperative pain. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS). 2015;14(8):122-127. e-ISSN: 2279-0853, p-ISSN: 2279-0861.

13. Praveen PVSB, Vijaya Chandra Reddy Konda, Lohit K. A prospective, randomized, double blind, comparative study of intramuscular nalbuphine hydrochloride, butorphanol tartrate and pentazocine lactate for post operative pain relief following abdominal hysterectomy. Int J Basic Clin Pharmacol. 2016;5(6):2326-2331.

14. Wang JJ, Mok MS, Lippmann M. Comparative analgesic efficacy of epidural nalbuphine, butorphanol, meperidine and morphine. Anesthesia and Analgesia. 1988;67(2):248.

15. Gomes VH, Oliveira RL, Marques JL, Coelho CM, Silva MF. Comparison of the sedative effects of nalbuphine and butorphanol, alone or in combination with acepromazine in dogs. Vet Anaesth Analg. 2018;45(1):68-72. DOI: 10.1016/j.vaa.2017.08.003. Epub 2017 Sep 15. PMID: 29183660.

16. Zucker JR, Neuenfeldt T, Freund PR. Respiratory effects of nalbuphine and butorphanol in anesthetized patients. Anesth Analg.1987;66:879-81.

17. Malek, J, Pocta J. Comparative study of the new analgesics Tramadol, Butarphanol, Nalbuphine and Buprenorphine. Acta Anaesthesiologica Melitensis. 1988;1(6):6-11.

18. Babu S, Gupta BK, Gautam GK. A comparative study for post operative analgesia in the emergency laparotomies: Thoracic epidural ropivacaaine with nalbuphine and ropivacaine with butorphanol. Anesthesia, Essays and Researches. 2017;11(1):155.

19. Kim DH, Park CH. A effectiveness of butorphanol and nalbuphine as utilized with ketorolac in patient controlled analgesia after total abdominal hysterectomy. The Korean Journal of Pain. 1998;11(2):263-7.

20. Priti M Chawda, Mayuresh K Pareek, Ketan D Mehta. Effect of Nalbuphine on Haemodynamic Response to Orotracheal Intubation. Journal of Anaesthesiology Clinical Pharmacology. 2010;26(4):458–460.
21. Ahsan-ul-Haq M, Kazmi EH, Rao ZA. Nalbuphine prevents haemodynamic response to endotracheal intubation. Journal of the College of Physicians and Surgeons--pakistan: JCPSP. 2005;15(11): 668-670.

© 2022 Ninave et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/79380